Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET CELEBRATION, Fla. , Nov. 18, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will co-host an
Toggle Summary KemPharm Reports Third Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET Corporate   and Regulatory Highlights: Announced expanded relationship with Corium through new consultation services agreement to provide revenue through March 2022 Announced issuance of two
Toggle Summary KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020 , 8:00 a.m. ET Q3 2020 Results Conference Call and Live Audio Webcast Scheduled for Thurs day , Oct 29 , 2020, 4 : 3 0 p.m. ET CELEBRATION, Fla. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
CELEBRATION, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in two oral
Toggle Summary KemPharm and Corium Expand Relationship with New Consultation Services Agreement
New agreement provides additional revenue potentially through Q1 2022 CELEBRATION, Fla. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has expanded its
Toggle Summary KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
CELEBRATION, Fla. , Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. ( KemPharm , or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today filed a preliminary proxy statement on Schedule 14A (the Preliminary Proxy
Toggle Summary KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies
Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program ® to collect data and create a more informed opioid prescribing environment CELEBRATION, Fla. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company
Toggle Summary KemPharm to Present at Upcoming September Investor Conferences
Presentations to Highlight Corporate, Regulatory and Pipeline Advancements CELEBRATION, Fla. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that its president and
Toggle Summary KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA
CELEBRATION, Fla. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020 , with the
Toggle Summary KemPharm Reports Second Quarter 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Corporate and Regulatory Highlights: Received Day-74 Letter for KP415 NDA; FDA has set PDUFA date of March 2, 2021 Announced that Corium, Inc. , a portfolio company of GPC, will lead all